ArticleAnnals of surgical oncology2026
Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study).
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Neoadjuvant Chemoimmunotherapy for Clinically Node-Negative NSCLC: Addressing an Evidence Gap.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Age 70 Stratifies Textbook Outcome after Esophagectomy, but Too Weakly to Guide Individual Decisions.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe oncologic appropriateness of segmentectomy for centrally located small-sized non-small-cell lung cancer (NSCLC) remains unclear. This study evaluated the outcomes of segmentectomy compared with lobectomy for centrally located clinical stage IA NSCLC.
methodsThis retrospective multicenter cohort study used the CReGYT-02 database from 17 Japanese institutions. Patients with clinical stage IA NSCLC (8th edition), tumor ≤3 cm, and consolidation-to-tumor ratio > 0.5 who underwent segmentectomy or lobectomy between 2012 and 2016 were included. Tumors located in the outer one-third of the lung parenchyma were excluded. Outcomes included recurrence-free survival, overall survival, recurrence patterns, and performance status and treatment at recurrence or diagnosis of other cancers. Kaplan-Meier analysis and Cox proportional hazards models were performed before and after inverse probability of treatment weighting.
resultsAmong 479 eligible patients, 26 underwent segmentectomy and 453 lobectomy. After inverse probability of treatment weighting, segmentectomy was not associated with inferior recurrence-free survival (hazard ratio 0.71; 95% confidence interval 0.31-1.67) or overall survival (hazard ratio 1.12; 95% confidence interval 0.46-2.70). Recurrence occurred in 7.7% after segmentectomy and 21.0% after lobectomy; no locoregional recurrences occurred after segmentectomy. All patients in the segmentectomy group maintained performance status 0-1 and received treatment at recurrence or diagnosis of other cancers.
conclusionsSegmentectomy was not associated with worse oncologic outcomes or increased locoregional failure compared with lobectomy among highly selected patients with centrally located small-sized NSCLC. However, because the segmentectomy cohort was very small, these findings should be interpreted cautiously and require validation in larger prospective studies.
Indexed as
Identifiers
42576113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.